IP Library Granted Patent US 7,569,358
Granted Patent B2
US 7,569,358 · App. 11/389,934 · Granted Aug 4, 2009

Doxorubicin immunoassay

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,569,358
App. No.
11/389,934
Granted
Aug 4, 2009
Kind
B2
Abstract

Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.

Claims (23)

1. An immunoassay for determining the amount of doxorubicin in a human sample comprising providing a mixture of a) said sample, b) an antibody selectively reactive with doxorubicin and not substantially cross-reactive with doxorubicin aglycone and c) a known amount of a conjugate of a carrier having either a reactive thiol or amino group with either a compound of the formula:

wherein A is

Y is an organic spacing group;

X is a functional group capable of binding to said carrier through said amino or thiol group; and

p is an integer from 0 to 1;

or a compound of the formula:

wherein X, Y and p are as above and B is

 or a mixture of a known amount of the conjugates formed from the compound of formula II-A and II-B as described above, wherein said conjugate competes with said doxorubicin in the sample for binding sites on said antibody;

and allowing the doxorubicin in the sample and said conjugate in said mixture to competitively bind in said mixture with said antibody and thereafter measuring the amount of said conjugate in said mixture which is bound to said antibody to determine the amount of doxorubicin in the sample, wherein the measured amount of said conjugate bound to said antibody is inversely proportional to the amount of doxorubicin present in the sample.

2. The immunoassay of claim 1 , wherein said antibody is generated from an immunogen comprising an immunogenic carrier having a reactive thiol or amino group conjugated to either a compound of the formula:

or a compound of the formula:

or a mixture of the immunogens formed from the compound of formula II-A and II-B as described above;

wherein p, Y, A and B are as defined in claim 1 and X is a functional group capable of binding to said immunogenic carrier through said amino or thiol group.

3. The immunoassay of claim 2 , wherein the compound conjugated to said immunogenic carrier for generating the antibodies has the formula:

wherein p, X, Y and A are as defined in claim 2 .

4. The immunoassay of claim 3 , wherein the immunogenic carrier contains a reactive thiol group and X linked to the immunogenic carrier is a functional group capable of reacting with said thiol group.

5. The immunoassay of claim 4 , wherein X is

6. The immunoassay of claim 5 , wherein Y is lower alkyl.

7. The immunoassay of claim 6 wherein the reactive thiol group of the immunogenic carrier has the structure

wherein v is an integer from 1 to 6.

8. The immunoassay of claim 1 , wherein the antibody is attached to a solid support.

9. The immunoassay of claim 8 , wherein the solid support is microtiter plates.

10. The immunoassay of claim 8 , wherein the solid support is nanoparticles.

Assignments (2)
SECURITY INTEREST Recorded Nov 17, 2015
From: SALADAX BIOMEDICAL, INC.
To: SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Reel/Frame 037126/0733 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2006
From: SALAMONE, SALVATORE J.; COURTNEY, JODI BLAKE; HE, SHU
To: SALADAX BIOMEDICAL INC.
Reel/Frame 017689/0719 →